Q4 2021 Inhibikase Therapeutics Inc Earnings Call
Operator: Greetings, welcome to Inhibikase Therapeutics, Inc. fourth quarter full year 2021 financial results.
At this time, all participants are in listen-only mode.
A question and answer session will follow the formal presentation.
If anyone should require operator assistance during the conference, please press star zero from your telephone keypad.
Please note this conference is being recorded.
At this time, I'll now turn the conference over to Alexander Lobo with Stern Investor Relations. Alexander, you may now begin.
Alexander Lobo: Good morning, and welcome to Inhibikase Therapeutics full year 2021 financial results conference call and audio webcast.
With me today are Dr. Milton Werner, Chief Executive Officer, and Joseph Frattaroli, Chief Financial Officer.
Yesterday afternoon, Inhibikase Therapeutics issued a press release announcing financial results for the full year ended December 31, 2021.
We encourage everyone to read yesterday's press release as well as Inhibikase's annual report on Form 10-K for the full year of 2021, which is being filed with the SEC.
The company's press release and annual report are also available on Inhibikase's website at inhibikase.com.
In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference.
Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast April 1st, 2022.
Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov.
The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast except as may be required by applicable securities law.
The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast except as may be required by applicable securities law.
As may be required by applicable securities law.
With that said, I would now like to turn the call over to Dr. Milton Werner. Milton?
Milton Werner: Thank you Alex and welcome everyone to Inhibikase Therapeutics' full year 2021 earnings call.
2021 was a really important year for us as we transitioned into a clinical stage company that has made significant progress in a very short period of time. We've advanced our lead program IkT-148009 for Parkinson's disease into the clinic and rapidly moved from dosing healthy volunteers in a phase one study into dosing patients with mild to moderately advanced Parkinson's disease in our phase one B extension study.
With mild to moderately advanced Parkinson's disease.
Our phase one B extension study.
Just recently, we presented results from both of these studies at the annual ADPD meeting in Barcelona, Spain.
I will talk a little bit more about these results later on but in short we believe these data continue to validate the safety and therapeutic potential of IkT-148009.
I will talk a little bit more about these results later on but in short we believe these data continue to validate the safety and therapeutic potential of IkT-148009.
In our early-stage pipeline, we have continued to make progress in advancing IkT-148009 in animal models of multiple system atrophy, as well as IkT-001Pro towards an IND filing. We expect to provide further updates on both programs in the second quarter.
And our early stage pipeline, we have continued to make progress in advancing our case, you're fortunate or nine in animal models of <unk>.
Full system atrophy, as well as I K T O one pro towards an IND filing we expect to provide further updates on both programs in the second quarter.
Lastly, to support all of these efforts, we were pleased to strengthen our balance sheet last year to support our development efforts well into 2023.
Taken together, we believe that all of these efforts position us for a year of execution on that pipeline as we seek to improve the lives of patients and create value for our shareholders.
Let me start by highlighting the progress we've made in our lead program, IkT-148009.
Let me start by highlighting the progress we've made in our lead program, IkT-148009.
As many of you know, IkT-148009 is a highly-selective, non-receptor Abelson tyrosine kinase or [inaudible] inhibitor.
Tyrosine kinase inhibitors have a 25-year history of clinical use. However, only a few tyrosine kinase inhibitors have been approved for non-oncology indications.
Drugs in the Abelson tyrosine kinase inhibitor class generally cannot reach a therapeutic dose in the central nervous system. IkT-148009 is different in this regard as we designed the molecule to have a predicted low toxicity profile and to have the ability to cross the blood-brain barrier and accumulate in the brain features that were well, that were validated in animal models, and extensive toxicology studies.
Drugs in the Abelson tyrosine kinase inhibitor class generally cannot reach a therapeutic dose in the central nervous system. IkT-148009 is different in this regard as we designed the molecule to have a predicted low toxicity profile and to have the ability to cross the blood-brain barrier and accumulate in the brain features that were well, that were validated in animal models, and extensive toxicology studies.
I K T 14, or not is different in this regard as we designed the molecule to have a predicted low toxicity profile.
And so having the ability to cross the blood brain barrier and accumulated in the brain features that were well that were validated in animal models and extensive toxicology studies.
Our randomized phase one dose-escalation study in older and elderly healthy volunteers continues to evaluate the safety, tolerability, and pharmacokinetics of IkT-148009.
The primary objective of the study has been to identify the maximum tolerated dose and PK profile in single and multiple ascending dose settings.
The study, which was initiated in February of 2021, has demonstrated exposures that are very high, for example, covering an area under the curve or AUC that is greater than 200,000 nanogram per milliliter out of 325 milligram dose given once daily and displays linear dose proportionality in the blood.
There have been no clinically significant adverse events observed across 88 subjects in single or seven-day dosing experiments up to a 325-milligram dose. Penetration into the central nervous system was confirmed by measures of IkT-148009 in the spinal fluid.
There have been no clinically significant adverse events observed across 88 subjects in single or seven-day dosing experiments up to a 325-milligram dose. Penetration into the central nervous system was confirmed by measures of IkT-148009 in the spinal fluid.
Penetration into the central nervous system was confirmed by measures of IkT-148009 in the spinal fluid.
Turning now to the phase IB extension study, which is a three to one randomized placebo-controlled dose-escalation trial with seven-day dosing.
This portion of the study is evaluating the safety, tolerability, and pharmacokinetics of seven-day dosing of IkT-148009 at three escalating dose levels in patients with mild to moderately advanced Parkinson's disease. The study is also assessing motor and non-motor function, you have got motility and plans to measure alpha silicon aggregate clearance as exploratory endpoints.
This portion of the study is evaluating the safety, tolerability, and pharmacokinetics of seven-day dosing of IkT-148009 at three escalating dose levels in patients with mild to moderately advanced Parkinson's disease. The study is also assessing motor and non-motor function, you have got motility and plans to measure alpha silicon aggregate clearance as exploratory endpoints.
The study is also assessing motor and non-motor function, you have got motility and plans to measure alpha silicon aggregate clearance as exploratory endpoints.
In the first cohort that has been enrolled and analyzed, there were no clinically significant adverse events observed. One case of pneumonia, one case of spinal headache following spinal fluid sampling, and one case of dermatitis, were all that was observed in the eight-patient cohort.
One case of pneumonia, one case of spinal headache, following spinal fluid sampling and one case of dermatitis, where all that was observed in the eight patient cohort.
Clinical pharmacology of IkT-148009 patients closely paralleled the clinical pharmacology of IkT-148009 in older, healthy volunteers.
Trends and changes in motor and non-motor features of the disease are observed but cannot be personally interpreted from a short dosing duration of just eight patients. These early results are encouraging and we look forward to completing cohorts two and three in the study.
Taken together, we believe these promising results for both phase I and phase IB studies continued to validate the safety and therapeutic potential of Ikt-148009 as a disease-modifying treatment for Parkinson's and stages of the design and the initiation of the phase III program.
Taken together, we believe these promising results for both phase I and phase IB studies continued to validate the safety and therapeutic potential of Ikt-148009 as a disease-modifying treatment for Parkinson's and stages of the design and the initiation of the phase III program.
Looking ahead, we are working diligently to initiate our phase IIA clinical study. This study will be a three to one randomized double blind 12-week dosing trial that will evaluate the safety and tolerability of three doses of Ikt-148009 in up to 120 patients diagnosed with Parkinson's disease, who have not yet progressed to the need for symptomatic treatment.
Evaluate the safety and Tolerability of three doses of I K T sport commander nine and up to 120 patients diagnosed with Parkinson's disease, who have not yet progressed to the need for symptomatic treatment.
The trial will also measure motor and non-motor function inside and outside of the brain at secondary endpoints as well as evaluate whether IkT-148009 leads to a reduction or clearance of pathogenic opposite aggregates as exploratory endpoints.
We expect to initiate and dose the first patient in the second quarter of 2022, subject to agreement with the FDA.
Before I turn the call over to Joe to review our financials, I want to touch on a couple of our early-stage programs.
As we seek to broadly apply our learnings and emerging generation beyond Parkinson's disease, we are currently evaluating Ikt-148009 in animal models of multiple system atrophy or MSA.
This work is part of the grant that we received from the US National Institutes of Neurological Disease and Stroke and the National Institutes of Health in 2021.
MSA is a rare rapidly progressing neurodegenerative neurodegenerative movement disorder that affects both the central and autonomic nervous systems. Similar to Parkinson's MSA is characterized by pathological opposite aggregation. This may lead to cell dysfunction and degeneration of neurons.
MSA is a rare rapidly progressing neurodegenerative neurodegenerative movement disorder that affects both the central and autonomic nervous systems. Similar to Parkinson's MSA is characterized by pathological opposite aggregation. This may lead to cell dysfunction and degeneration of neurons.
Similar to Parkinson's MSA is characterized by pathological opposite aggregation.
This may lead to cell dysfunction, and degeneration of neurons M.
MSA affects approximately 20,000 people in the US and there are currently no approved therapies to slow or halt the progression of this disease.
Our preclinical studies are evaluating whether inhibition of [inaudible] could have a therapeutic benefit in MSA. And we've previously published that mechanistic paper on the potential role of [inaudible] disease in the peer-reviewed journal Neurobiology of Disease. That publication occurred in 2021.
Our preclinical studies are evaluating whether inhibition of [inaudible] could have a therapeutic benefit in MSA. And we've previously published that mechanistic paper on the potential role of [inaudible] disease in the peer-reviewed journal Neurobiology of Disease. That publication occurred in 2021.
And we've previously published that mechanistic paper on the potential role of [inaudible] disease in the peer-reviewed journal Neurobiology of Disease.
That publication occurred in 2021.
Depending on the preclinical results in animal models of MSA and subject to agreement with the FDA and equivalent regulatory bodies in the European Union, we may advance IkT-148009 into a phase IIA clinical study in the third quarter of 2022. But that advancement will only occur if we see positive therapeutic benefits IkT-148009 in at least one animal model.
But that advancement will only occur if we see positive therapeutic benefit.
K T 14, a dine in at least one animal model.
Finally, we are continuing to advance Ikt-001Pro, our pro-drug formulation of [inaudible] methylate, which we have designed as a potentially safer, better-tolerated treatment for [inaudible] sensitive cancers, such as stable phase chronic myeloid leukemia.
We are in the process of collecting stability data for the manufactured product. And now expect to submit the investigational new drug application in the second quarter of 2022. Following receipt of the Study May Proceed Letter and other agreements with the FDA, we intend to commence bioequivalence studies in accordance with the 505B2 regulatory pathway. Now, let me turn the call over to Joe Frattaroli, our Chief Financial Officer. Joe?
And now expect to submit the investigational new drug application in the second quarter of 2022.
Following receipt of the study May proceed letter and other agreements with the F D. A.
Tend to commence bioequivalence studies in accordance with the problem of five B two regulatory pathway.
Now, let me turn the call over to Joe for out of Raleigh, Our Chief Financial Officer Joe.
Joseph Fratteroli: Thank you, Milton. Let me review our financials for the year ended December 31, 2021.
Let me review our financials for the year ended December 31, 2021 .
Rent revenue was $3.1 million for the year ended December 31, 2021, compared to $0.7 million for fiscal year 2020, an increase of approximately 343%.
During 2020, the company's focus was shifted towards advancing its phase I clinical trial plans, which did not result in any grant revenue.
During 2021, utilizing the additional capital resources from our June 2021 [inaudible] one offering, we were able to focus on our clinical trial activities in addition to our grant-related research activities.
Research and development expenses were $11.4 million for the year ended December 31, 2021, compared to $0.9 million for the year end 2020, an increase of approximately 167%.
At year end 2020, an increase of approximately 167%.
The significant increase for fiscal 2021 was primarily due to an $8 million increase in non-granulated research conducted as we ramped up our ongoing human clinical trials.
Our grant-related research activities also increased during fiscal 2021 by approximately $2.4 million over the prior year.
Selling general and administrative expenses were $6.5 million for the year ended December 31, 2021, compared to $2.6 million for the same period 2020, an increase of approximately 150%.
The significant increase for fiscal 2021 was primarily due to ordinary general and administrative costs incurred during our first full year of operating as a public company after our December 2020 initial public offering.
After our December 2020 initial public offering.
For the year ended December 31, 2021, we reported a net loss of approximately $14.8 million or 81 cents per share, compared to a net loss of approximately $2.8 million about 35 cents per share for the full year 2020.
Net loss of approximately $2.8 million about 35 cents per share for the full year 2020.
As of December 31, 2021, Inhibikase had approximately $40.8 million in cash.
The company anticipates its cash runway would be sufficient to fund operations into the third quarter of 2023.
That concludes our financial statements. I'd like to hand, the call back over to Milton for closing remarks.
Milton Werner: Thank you, Joe. I'd like to conclude by saying that we are very excited by the work we are doing and believe that we have an opportunity to significantly improve the lives of patients suffering from devastating neurodegenerative diseases, such as Parkinson's. As we look ahead, we intend to share more about our development strategy and recently presented data for IkT-148009 including the upcoming phase IIA study at our virtual KOL investor event, which will take place on April 20th.
Offering from devastating neurodegenerative diseases, such as Parkinson's as we look ahead, we intend to share more about our development strategy and recently presented data for I can't eat fortunate or nine including the upcoming phase III study at our virtual care K, well investor event, which will take place on April 20th we've.
We view 2022 as a year of execution across all of our clinical and preclinical pipeline programs and look forward to providing updates throughout the year.
We'd like to thank you, our shareholders, and partners for their continued support and I would now like to open the call to questions. Operator?
Operator: Thank you. We'll now begin the question and answer session. If you'd like to ask a question, please press star one from your telephone keypad and the confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. If you're using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please while we poll for questions.
Well now begin the question and answer session.
If you'd like to ask a question. Please press star one from your telephone keypad and a confirmation tone will indicate your line is in the question queue.
You May press Star two if you like to move your question from the queue.
This is city speaker equipment, it may be necessary to pick up your handset before pressing the star keys.
One moment, please while we poll for questions.
Yeah.
Yeah.
Okay.
Once again, if you'd like to ask a question this morning, you may press star one to enter the queue. We'll pause for a few moments to assemble the queue.
This morning, you May press star one to enter the queue.
For a few moments to assemble the queue.
Yeah.
Yeah.
Yeah.
Thank you. This will conclude today's conference. We thank you for your participation and you may now disconnect at this time and have a wonderful day.
For your participation and you may now disconnect at this time and have a wonderful day.